Stip Emmanuel, Chouinard Sylvie, Boulay Luc Jean
Department of Psychiatry, Centre de Recherche Fernand-Seguin, Hôpital Louis-Hippolyte Lafontaine, Université de Montréal, 7331, rue Hochelaga Montréal, Québec, H1N 3V2, Canada.
Prog Neuropsychopharmacol Biol Psychiatry. 2005 Feb;29(2):219-32. doi: 10.1016/j.pnpbp.2004.11.004. Epub 2005 Jan 16.
The aim of this critical review is to address that the study of cognition and antipsychotics is not always driven by logic and that research into real pro-cognitive drug treatments must be guided by a better understanding of the biochemical mechanisms underlying cognitive processes and deficits. Many studies have established that typical neuroleptic drugs do not improve cognitive impairment. Atypical antipsychotics improve cognition, but the pattern of improvement differs from drug to drug. Diminished cholinergic activity has been associated with memory impairments. Why atypical drugs improve aspects of cognition might lie in their ability to increase dopamine and acetylcholine in the prefrontal cortex. An optimum amount of dopamine activity in the prefrontal cortex is critical for cognitive functioning. Another mechanism is related to procedural learning, and would explain the quality of the practice during repeated evaluations with atypical antipsychotics due to a more balanced blockage of D2 receptors. Laboratory studies have shown that clozapine, ziprasidone, olanzapine, and risperidone all selectively increase acetylcholine release in the prefrontal cortex, whereas this is not true for haloperidol and thioridazine. A few studies have suggested that cholinomimetics or AChE inhibitors can improve memory functions not only in Alzheimer's disease but also in other pathologies. Some studies support the role of decreased cholinergic activity in the cognitive deficits while others demonstrate that decreased choline acetyltransferase activity is related to deterioration in cognitive performance in schizophrenia. Overall, results suggest the hypothesis that the cholinergic system is involved in the cognitive dysfunctions observed in schizophrenia and that increased cholinergic activity may improve these impairments. Furthermore, a dysfunction of glutamatergic neurotransmission could play a key role in cognitive deficits associated with schizophrenia. Further meta-analysis of various clinical trials in this field is required to account for matters on the grounds of evidence-based medicine.
这篇批判性综述的目的是指出,认知与抗精神病药物的研究并非总是由逻辑驱动,对真正的促认知药物治疗的研究必须以对认知过程和缺陷背后生化机制的更好理解为指导。许多研究已证实,传统抗精神病药物并不能改善认知障碍。非典型抗精神病药物可改善认知,但改善模式因药物而异。胆碱能活性降低与记忆障碍有关。非典型药物改善认知方面的原因可能在于它们能够增加前额叶皮质中的多巴胺和乙酰胆碱。前额叶皮质中适量的多巴胺活性对认知功能至关重要。另一种机制与程序性学习有关,这可以解释在使用非典型抗精神病药物进行重复评估期间的实践质量,这是由于对D2受体的更平衡阻断。实验室研究表明,氯氮平、齐拉西酮、奥氮平和利培酮均能选择性增加前额叶皮质中的乙酰胆碱释放,而氟哌啶醇和硫利达嗪则不然。一些研究表明,拟胆碱药或乙酰胆碱酯酶抑制剂不仅可以改善阿尔茨海默病患者的记忆功能,还可以改善其他病症患者的记忆功能。一些研究支持胆碱能活性降低在认知缺陷中的作用,而另一些研究则表明胆碱乙酰转移酶活性降低与精神分裂症患者认知表现的恶化有关。总体而言,结果提示了这样一种假说,即胆碱能系统参与了精神分裂症中观察到的认知功能障碍,胆碱能活性增加可能改善这些损害。此外,谷氨酸能神经传递功能障碍可能在与精神分裂症相关的认知缺陷中起关键作用。需要对该领域的各种临床试验进行进一步的荟萃分析,以便基于循证医学来解释相关问题。